LEWISVILLE, Texas--(BUSINESS WIRE)--med fusion, an integrated Molecular Center of Excellence and clinical trials service organization, announced the expansion of its molecular diagnostic testing services to include the Oncotype DX® assays, which are available to oncologists nationwide. These multi-gene tests can help physicians make individual treatment decisions for their cancer patients by identifying which invasive breast cancer patients may likely benefit from chemotherapy as well as assessing recurrence risk in Ductal Carcinoma In Situ (DCIS), colon and prostate cancers.
